Joseph P Casazza

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/310227/publications.pdf

Version: 2024-02-01

22 papers 3,656 citations

19 h-index

394421

677142 22 g-index

22 all docs 22 docs citations

times ranked

22

5025 citing authors

#	Article	IF	CITATIONS
1	Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial. Nature Medicine, 2022, 28, 1022-1030.	30.7	34
2	Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial. Lancet HIV, the, 2019, 6, e667-e679.	4.7	67
3	Principles Governing Establishment versus Collapse of HIV-1 Cellular Spread. Cell Host and Microbe, 2019, 26, 748-763.e20.	11.0	30
4	Randomized Clinical Trial to Assess the Impact of the Broadly Neutralizing HIV-1 Monoclonal Antibody VRCO1 on HIV-1 Persistence in Individuals on Effective ART. Open Forum Infectious Diseases, 2018, 5, ofy242.	0.9	23
5	Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies. Science Translational Medicine, 2017, 9, .	12.4	135
6	Multiple Origins of Virus Persistence during Natural Control of HIV Infection. Cell, 2016, 166, 1004-1015.	28.9	156
7	Selective Loss of Early Differentiated, Highly Functional PD1high CD4 T Cells with HIV Progression. PLoS ONE, 2015, 10, e0144767.	2.5	16
8	Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Science Translational Medicine, 2015, 7, 319ra206.	12.4	390
9	IFNγ ^{â^³} TNFα ^{â^³} IL2 ^{â^³} MIP1α ^{â^³} CD107a ⁺ PRF1 <spp65-specific -="" 1210-1218.<="" 2015,="" 70,="" a="" and="" associated="" biological="" death="" elderly="" gerontology="" humans.="" in="" independently="" is="" journals="" medical="" of="" response="" sciences="" sciences,="" series="" t-cell="" td="" time="" to="" with=""><td>sup>+3.6</td><td>лр>CD8 11</td></spp65-specific>	sup>+3.6	лр>CD8 11
10	The Phenotype of the Cryptococcus-Specific CD4+ Memory T-Cell Response Is Associated With Disease Severity and Outcome in HIV-Associated Cryptococcal Meningitis. Journal of Infectious Diseases, 2013, 207, 1817-1828.	4.0	113
11	Therapeutic Vaccination Expands and Improves the Function of the HIV-Specific Memory T-Cell Repertoire. Journal of Infectious Diseases, 2013, 207, 1829-1840.	4.0	52
12	A Phase I study evaluating the safety and immunogenicity of MVA85A, a candidate TB vaccine, in HIV-infected adults. BMJ Open, $2011,1,e000223-e000223.$	1.9	42
13	Preferential infection and depletion of <i>Mycobacterium tuberculosis</i> –specific CD4 T cells after HIV-1 infection. Journal of Experimental Medicine, 2010, 207, 2869-2881.	8.5	224
14	A Steady State of CD4+ T Cell Memory Maturation and Activation Is Established during Primary Subtype C HIV-1 Infection. Journal of Immunology, 2010, 184, 4926-4935.	0.8	23
15	Autocrine Production of \hat{I}^2 -Chemokines Protects CMV-Specific CD4+ T Cells from HIV Infection. PLoS Pathogens, 2009, 5, e1000646.	4.7	81
16	Immunisation with BCG and recombinant MVA85A induces long″asting, polyfunctional <i>Mycobacterium tuberculosis</i> â€specific CD4 ⁺ memory T lymphocyte populations. European Journal of Immunology, 2007, 37, 3089-3100.	2.9	206
17	Preferential Infection Shortens the Life Span of Human ImmunodeficiencyVirus-Specific CD4 + T Cells In Vivo. Journal of Virology, 2006, 80, 6801-6809.	3.4	67
18	Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation. Journal of Experimental Medicine, 2006, 203, 2865-2877.	8.5	293

#	Article	IF	CITATIONS
19	Immunologic Pressure within Class I-Restricted Cognate Human Immunodeficiency Virus Epitopes during Highly Active Antiretroviral Therapy. Journal of Virology, 2005, 79, 3653-3663.	3.4	20
20	T-Cell Subsets That Harbor Human Immunodeficiency Virus (HIV) In Vivo: Implications for HIV Pathogenesis. Journal of Virology, 2004, 78, 1160-1168.	3 . 4	351
21	A Novel Approach to the Analysis of Specificity, Clonality, and Frequency of HIV-Specific T Cell Responses Reveals a Potential Mechanism for Control of Viral Escape. Journal of Immunology, 2002, 168, 3099-3104.	0.8	190
22	HIV preferentially infects HIV-specific CD4+ T cells. Nature, 2002, 417, 95-98.	27.8	1,132